Zepp Health

Zepp Health is a turnaround with the hard part already showing in the numbers: after shedding its dependence on low-margin Xiaomi manufacturing, full-year 2025 revenue grew 41.8% to $258.9M with Amazfit-brand sales up 50.9%, and Q1 2026 kept pace at 33.8% growth to $51.5M while the operating loss narrowed 63% year-over-year to $6.3M with gross margin ticking up to 37.7% — a self-owned brand scaling as losses compress. The strategic assets are disproportionate to the company's size: a fully owned stack (Zepp OS, in-house AI chips, biometric algorithms, the Zepp app and Aura AI services), over 200 million devices shipped historically, and distribution across 150-plus countries — infrastructure that normally belongs to companies ten times its revenue. Its value-for-performance positioning is well aimed at the most defensible seam in the market: GPS multisport and rugged outdoor watches (T-Rex Ultra 2, Active Max, Cheetah) delivering multi-week battery and dual-band GPS at hundreds of dollars below Garmin's equivalents, in a category where Apple's daily-charge rectangle does not compete. The product-driven reacceleration of 2025-26 — new launches directly fueling each quarter's growth — shows the machine works, and with NYSE-listed currency, the wearables category consolidating toward players with real silicon-to-software integration, and the stock trading at a fraction of its revenue after the 2026 selloff, Zepp offers deep-value exposure to a growing, margin-improving global smartwatch franchise priced as if the turnaround weren't happening.

The market's verdict on the turnaround is written in the tape: Zepp shares slid roughly 70% during 2026 even as revenue grew, because the structure of the business remains hostile. Zepp is still unprofitable — a $6.3M operating loss in Q1 2026 on just $51.5M of revenue — and its Q2 2026 guidance of $63-68M implies growth decelerating to 6-14%, suggesting the 2025 reacceleration owed more to a product-launch cluster than a durable demand shift. The competitive geometry is the worst in consumer hardware: Garmin owns the premium sports segment with 37%-plus operating history and a fanatical installed base, Apple and Samsung own the mainstream wrist, Huawei and Xiaomi flood every price tier below, and Amazfit's value positioning leaves it perpetually one competitor price cut from margin erosion — while its 37.7% gross margin must fund an OS, chip development, AI services, and 150-country distribution that rivals amortize over five to fifty times the volume. A sub-$300M-revenue company carrying full-stack R&D is a structural mismatch that scale alone can fix, and scale is precisely what the guidance doesn't promise. The China-based manufacturing and engineering footprint adds tariff exposure in its most important growth market and the persistent valuation discount applied to US-listed Chinese companies — a discount that Zepp's Cupertino nameplate does not dissolve. Cash burn against a compressed market cap limits strategic room, and the wearables history books are unkind to value-tier players when categories consolidate: Fitbit grew faster than this at larger scale and still ended as a distressed sale. Growth without profits, in this category, has repeatedly proven to be a countdown, not a runway.